

Selection of Optimal Candidates for Preoperative Systemic Therapy (PST) for Primary Breast Cancer

Gabriel N. Hortobagyi, M.D., F.A.C.P.

Professor of Medicine

Director, Breast Cancer Research Program

The University of Texas

M. D. Anderson Cancer Center

Bethesda, March 26, 2007

Preoperative Systemic Therapy: Potential Advantages

- Improved Tumor Downstaging
 - Inoperable \longrightarrow Operable
 - Mastectomy \longrightarrow BCT
 - Improves the rate of breast conservation surgery
- Provides in vivo assessment of anti-tumor effects
- Provides opportunity to assess surrogate biological endpoints
- May expedite new drug development
- Early initiation of systemic therapy
- Inhibition of post-surgical growth spurt



Prospective Randomized Trials: Preoperative vs. Adjuvant Chemotherapy In LABC

Author	Year	# Pts	F/U Mos	OS (%)	DFS (%)
Schaake-Koning	1985	39	66	37	24
		34		37	24
Mauriac	1991	133	34	95 *	80
		134		88	79
Pierga	1992	200	36	93	68
		190		86	66
Scholl	1994	196	54	86 *	59
		194		78	55
Semiglazov	1994	137	53	86	81 *
		134		78	71
Gervasio	1994	81	120	57	42
		90		53	40

* $P < 0.05$

B-18

Overall and Disease-Free Survival



Breast-Conserving Surgery after PST

Randomized Phase III Trials of PST vs. ACT for Primary Operable Breast Cancer

Trial (n)	TNM	CT regimen	F/U in months	% pCR	BCS rate: NACT/ACT
NSABP B-18 (n=1523)	T ₁₋₃ N ₀₋₁	AC x 4	114	9	67/60 P=0.002
ECTO (n=892)	T ₁₋₃ N ₀₋₁	AP x 4 → CMF x 4	43	23	71/35 P<0.0001
EORTC 10902 (n=698)	T _{1c-4b} N ₀₋₁	FEC x 4	56	4	35/22 P N/A
ABCSCG (n=423)	T ₁₋₃ N ₀₋₂	CMF X 3	N/A	6	67/60 NS
S6 (N=390)	T ₁₋₃ N ₀₋₂	CAF 4	105	N/A	82/77 NS

What Patients are Optimal Candidates for Preoperative Chemotherapy for Primary Breast Cancer?

Simple answer:

All Patients known to be candidates for adjuvant chemotherapy are candidates for preoperative chemotherapy

Do All Patients Benefit Equally
from Preoperative
Chemotherapy?


How Should we Define pCR?

Definitions of Pathological Complete Remission (pCR)




- Malignant cells undetectable in breast and lymph nodes
- Invasive tumor undetectable in breast and lymph nodes (DCIS allowed)
- Invasive disease absent in breast
- Total or near total therapeutic effect in the primary tumor and evidence of therapeutic effect in lymph nodes, no metastasis

Outcome by Pathological Nodal Status After Preoperative Chemotherapy

Relapse-free Survival




Overall survival




Does Residual DCIS Influence Outcome in Patients Who Achieve pCR

Overall Survival



Disease-free survival



Definitions of Pathological Complete Remission (pCR)

- Malignant cells undetectable in breast and lymph nodes
- Invasive tumor undetectable in breast and lymph nodes (DCIS allowed)
- Invasive disease absent in breast
- Total or near total therapeutic effect in the primary tumor and evidence of therapeutic effect in lymph nodes, no metastasis

Is Pathological Complete Remission an Established Surrogate Marker for Survival?

- Patients who achieve pCR clearly have better survival rates than patients who do not.
 - Feldman LD, et al, *Cancer Res* 46:2578-81, 1986; Fisher B, et al, *J Clin Oncol* 16:2672-85, 1998; Kuerer HM, et al, *J Clin Oncol* 17:460-9, 1999

Questions

- If pCR rate increases will survival rate increase too?
- Is pCR of prognostic value in patients with ER+ breast cancer or those treated with endocrine therapy?
- Can patients who achieve a pCR be treated with less therapy? (surgery, RT, adjuvant systemic treatment)

Tools to Predict Response

- Individual predictive marker
 - Pathological
 - Biochemical
- Predictive Indices
- Functional Imaging (PET)
- Genetic Profiling

Factors Predictive of Higher pCR Rate

Factor	Higher pCR rate
--------	-----------------

Tumor size

Smaller size

Tumor grade

Higher grade

Histological type

Ductal > lobular

ER/PR

Negative

HER-2

Positive

Proliferative markers

Higher

MDR-1/pgp

Negative





Reported pCR Rates by Histological Type

Author (year)	No. pCR/Total No.	
	Lobular	Ductal
Cocquyt (03)	0/26	15/101
Chatuverdi (04)	0/31	44/260
Pu (05)	0/5	4/41
Cristofanilli (05)	4/122	138/908
Tubiana-Hulin (05)	1/118	67/742
Vincent-Salomon (05)	1/52	32/532
Total (%)	6/354 (1.7)	300/2584 (11.6)

Hormone Receptor Content is a Reliable Predictor of pCR

Trial/ author	No. of pts	Regimen	% HR negative	% pCR	
				HR-	HR+
Kemeny	54	FACVb	34	20.0	7.7
Ring	435	CMF, A/E	29	21.6	8.1
Bear	1211	AC	41	13.6	5.7
Bear	565	AC+T	43	22.8	14.1
GEPARDO	250	ddAD+/-T	44	15.4	1.1
GEPARDUO	913	ddAD/CA-D	26	22.8	6.2
GEPARTRIO	286	TAC/TAC-NX	32	36.6	10.1
Buzdar	1018	FAC+/-P	NA	20.6	5.6


Outcomes by pCR and ER Status




Pathological CR by Molecular Subtype

ER/PR/HER2
($p < .00000$)

% pCR



Gene Expression Profile
($p < 0.001$)



von Minckwitz G, et al.: 29th Annual SABCS; Dec 14-17, 2006; San Antonio, Tex.;
Rouzier R, et al.: *Clin Cancer Res* 11:5678-85, 2005

Individual Predictive Markers

- There is no individual pathological or molecular marker that can reliably predict response to PCT in an individual patient
- It could be hypothesized that patients with ER-negative, high-grade tumors with high S-phase fraction (or Ki-67) would be more likely to respond than tumors with the opposite characteristics

Tumor size, grade, histology and ER-status can be combined into a predictive index of pathologic CR

This pCR predictor is available at:

www.mdanderson.org/care_centers/breastcenter/dIndex.cfm?pn=448442B2-3EA5-4BAC-98310076A9553E63

The screenshot shows the MD Anderson Cancer Center website's "Chemotherapy Response Calculators" page. The page header includes the MD Anderson logo and navigation links: PATIENTS & PUBLIC, CANCER PROFESSIONALS, ABOUT M. D. ANDERSON, SITE MAP, and CONTACT US. Below the header is a search bar with "Care Centers & Departments" and "Diseases & Related Topics" dropdown menus. The main heading is "Breast Center Chemotherapy Response Calculators". The "Initial Management" section contains the following fields:

Preoperative chemotherapy	anthracycline-based chemotherapy x 3
Age	<input type="text"/> years
Tumor size (TNM)	0
Initial diameter (mm)	0 mm
Histologic type	ductal/other
Histologic grade	2
Estrogen receptor status	negative
Multicentricity	no

A "calculate" button is located at the bottom of the form.

Rouzier R et al: Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. *J Clin Oncol*, 23:8331-8339:2005.

Genetic Index (Oncotype Dx) to Predict pCR





Fig 2. Probability of pathologic complete response (pCR) as a function of Recurrence Score in the Istituto Nazionale Tumori-Milan (Italy) cohort. The Recurrence Score was calculated for each patient from the expression of 16 cancer-related genes and five reference genes. The red circles represent patients who had a pCR. The yellow circles represent patients who did not have a pCR.

L.Gianni et al. *JCO*, 2005; 23: 7265-7277


Supervised Cluster Analysis

Taxol[®] Clinical Response Markers (N=25)

- Top 100 Markers
- Ranked By AbsECombo



PR..130	PR..158	CR..136	PR..153	PR..111	PR..102	PR..120	PR..117	PR..126	SD..133	PR..159	PR..135	PR..127	PR..108	PR..116	PR..128	PR..106	PR..157	PR..123	PR..155	SD..110	SD..113	SD..156	SD..154	SD..139
---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------



L. Pusztai et al.,
ASCO 2003 #1

**Should We Switch Chemotherapy
Based on Response to the Initial
Regimen?**

Sequential Regimens

Author (study)	Treatments	pCR rate	<i>P</i>	PFS/ RFS	<i>P</i>
Thomas (MDACC)	VACP → VACP	NA	-	26	0.162
	VACP → VbMF	NA		46	
Smith (Aberdeen)	CVAP → CVAP	15	N/A	78%	0.022
	CVAP → Doc	31		93%	
Bear (B-27)	AC	13	<0.0001	69%	0.03
	AC → Doc	26		74%	
Von Minckwitz (GEPARTRIO)	TAC → TAC	24	<0.0001	N/A	N/A
	TAC → NX	6		N/A	

Primary Systemic
Therapy: Optimal for All
Patients?

*“All complex problems have
simple answers that are
invariably wrong”*

H. L. Mencken

A More Complex Answer

- PST is optimal for all patients who are candidates for systemic therapy.
- If indication for systemic therapy is uncertain, surgical removal is preferable.
- PST should be tailored to the biological profile of the primary tumor:

Treatment by Molecular Class

Class	Treatment	Additional Therapies
ER and/or PR-expressors	Aromatase inhibitors SERMs	± chemotherapy
HER2-amplified	Trastuzumab, lapatinib	± chemotherapy, hormone therapy
Triple-negative (ER, PR, HER2)	Chemotherapy (Platinum salts [?])	± bevacizumab
Basaloid	EGFR-inhibitors (?)	Platinum salts (?)

Hortobagyi GN, 2007

When is PST Not Indicated

- PST is Not Indicated when:
 - Systemic Therapy is not indicated
 - Primary and or LN metastases cannot be measured
 - Patient is not compliant
 - Multidisciplinary team is not available



THE UNIVERSITY OF TEXAS
MD ANDERSON
CANCER CENTER